Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

Abstract

Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the development of structurally related second-generation taxanes.

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

“…[23][24][25] In vivo pharmacokinetics and organ distribution studies Pharmacokinetics of the prepared Nps in Swiss albino mice was performed following ethically approved protocols in four animals in each group (n=4) and four animals in the control group. Samples at a dose of 10 mg/kg of DOCT (reconstituted as prescribed 26 using ethanol/polysorbate 80/saline) and Nps (with an equivalent dose of DOCT) in sterile 0.9% saline were injected intravenously through the lateral tail vein. At specific time points, blood was drawn through the retro-orbital sinuses to Acid Citrate Dextrose vials.…”

Knockout of mouse Cyp3a gene enhances synthesis of cholesterol and bile acid in the liver

“…) mouse is a valuable research tool in studies on drug metabolism and drug-induced toxicity in vivo ( 25,26 ). However, the physiological role of CYP3A has not been clearly elucidated in in vivo experiments.…”

Enriched variations in TEKT4 and breast cancer resistance to paclitaxel

“…Among chemotherapeutic agents, paclitaxel, which belongs to the group of taxanes (mitotic inhibitors and anti-microtubule agents), has shown great efficacy against breast cancer 2 . Over the past 10 years, the use of anthracycline-based chemotherapy has declined, and the majority of patients with breast cancer are instead receiving taxane-based chemotherapy 3 .…”